Almirall/Forest COPD drug disappoints in Phase III
This article was originally published in Scrip
Executive Summary
AlmirallandForest Laboratories' lead candidate, aclidinium bromide, an investigational treatment for chronic obstructive pulmonary disease (COPD), has shown disappointing, though positive, results in two Phase III studies.